Updated plan:

1. [✓] Search the biomedical literature for studies that deeply characterize TIL phenotypes in at least two distinct human solid malignancies.
2. [✓] Extract comparable phenotypic features, including T-cell subsets, exhaustion/activation markers, clonality, tissue residency, and functional state.
3. [✓] Compare whether the reported TIL phenotypes converge across malignancies and note important differences or disease-specific features.
4. [✓] Record high-value findings and provenance in the evidence graph.
5. [✓] Synthesize the evidence and conclude with the required decision.

## Evidence synthesis

Yes. Detailed characterization of tumor-infiltrating lymphocytes in distinct human solid malignancies reveals substantial **phenotypic similarities**, although the similarities are best understood as shared cellular states rather than an identical, universal TIL profile.

A directly comparative single-cell analysis spanning breast cancer, melanoma, colorectal cancer, lung cancer, and head-and-neck cancer identified a shared T-cell transcriptional signature across tumor types, while also finding cancer-specific features layered onto that common program (PMID:36232369; source: `call_lu5hzcqb1hHXIAMaPyFNFBhR`).

### Shared features

1. **CD8-enriched, antigen-experienced populations**  
   CD8-positive TILs are commonly prominent in human solid tumors and frequently display evidence of chronic antigen exposure, clonal expansion, cytotoxic programming, and tumor reactivity.

2. **Tissue-resident memory-like states**  
   CD69- and CD103-positive, often CD49a-positive, CD8 TILs are repeatedly described in melanoma, ovarian, colorectal, breast, and other solid malignancies. These cells frequently show tissue-resident memory, tumor-reactive, or progenitor-like properties. Their presence is often associated with improved prognosis or response to checkpoint blockade, though the association is tumor- and context-dependent (sources: `call_ZEVLwuEyOrG0cQiQVOWCW8lJ`, `call_CuYEz3W9ZiSoZASNuRe9RJcd`).

3. **Activation and cytotoxic programs**  
   Across tumor types, TILs can express cytotoxic and interferon-response programs, including genes associated with granzyme/perforin activity and inflammatory signaling. These programs may coexist with memory or exhaustion-associated features.

4. **Checkpoint-receptor-rich exhaustion continua**  
   Rather than a simple exhausted versus non-exhausted dichotomy, human TILs commonly occupy a continuum from progenitor or stem-like exhaustion to more terminal dysfunction. Recurrent inhibitory receptors include PD-1, TIM-3, LAG-3, and TIGIT (PMID:35961204; sources: `call_nvvlCWLPAlnRMSLFkCdz0BzX`, `call_VDoX2IWq9PPYTPz8twoumUst`).

5. **Memory/TRM and immunotherapy responsiveness**  
   In a study incorporating approximately 9,000 human tumors and single-cell datasets, memory and tissue-resident programs were found across solid tumors. In melanoma, patients responding to anti-PD-1 therapy had more memory/TRM-scoring CD8 TILs, which expanded after treatment (PMID:35537413; source: `call_CuYEz3W9ZiSoZASNuRe9RJcd`).

### Important differences between malignancies

The shared programs do not imply equivalent TIL composition or function across cancers.

- The **CD8:CD4 ratio** varies substantially.
- Overall T-cell infiltration differs; for example, colorectal and gastric adenocarcinomas can have lower T-cell infiltration than renal clear-cell and lung adenocarcinomas.
- The abundance of **CD69-positive/CD103-positive TRM-like cells** differs by tumor type, stage, molecular subtype, and treatment history.
- Checkpoint-receptor coexpression is recurrent but not quantitatively uniform.
- Some TRM-like or progenitor-exhausted cells retain proliferative and cytotoxic potential, whereas terminally exhausted cells may have reduced cytokine production and poor proliferative capacity.
- TCR clonality shows partial convergence—tumor-reactive cells can be clonally expanded and enriched for TRM or exhaustion-like programs—but the dominant clonotypes, antigen specificity, repertoire structure, and response to checkpoint blockade remain tumor- and patient-specific (sources: `call_lu5hzcqb1hHXIAMaPyFNFBhR`, `call_CuYEz3W9ZiSoZASNuRe9RJcd`, `call_XaXCNVUShpDbie8IZDh0D7Wo`).

## Interpretation

The strongest conclusion is:

- **Yes**, different human solid malignancies contain TILs with recurring phenotypic states: CD8-positive, antigen-experienced, tissue-resident-memory-like, cytotoxic/interferon-responsive, and checkpoint-receptor-rich progenitor-to-terminal exhaustion states.
- **No**, they do not share one fixed quantitative phenotype. The frequency, organization, clonality, and functional competence of these states differ considerably among malignancies and patients.

Thus, the similarities are biologically meaningful but should be interpreted as **conserved T-cell differentiation programs**, not as identical marker profiles across all tumors.

FINAL DECISION: YES